Low-density lipoprotein receptor mRNA (LDLR mRNA)

Low-density lipoprotein receptor (LDLR) mRNA is the messenger RNA transcript that encodes the LDLR protein, a critical cell-surface receptor responsible for the endocytosis and clearance of LDL cholesterol from the blood (1.2.4). The stability and translation of LDLR mRNA are tightly regulated at the post-transcriptional level, particularly through its 3' untranslated region (UTR), which contains AU-rich elements (AREs) that serve as binding sites for various regulatory proteins and microRNAs (1.3.1, 1.4.2). Mutations that reduce the expression or function of this transcript lead to Familial Hypercholesterolemia (FH), resulting in severely elevated plasma cholesterol and a high risk of premature atherosclerosis (1.1.1, 1.5.5). As a therapeutic target, LDLR mRNA is modulated to increase the density of LDL receptors on hepatocytes. Small molecules like berberine have been shown to stabilize the mRNA by activating the ERK signaling pathway, thereby increasing its half-life and subsequent protein production (1.3.2, 1.3.4). Additionally, modern biotechnological approaches are exploring mRNA replacement therapies, where functional LDLR mRNA is delivered to the liver using exosomes or lipid nanoparticles to bypass genetic defects in patients with homozygous FH (1.1.1, 1.1.2). Other strategies involve inhibiting microRNAs like miR-33 that target the LDLR mRNA for degradation, providing a novel avenue for lipid-lowering therapy beyond traditional transcriptional induction by statins (1.2.3, 1.4.3).

Other names

Low-density lipoprotein receptor messenger RNALDLR transcriptLDLR 3' UTRLDLR mRNA transcript

Drugs targeting LDLR mRNA primarily work through mRNA stabilization, where small molecules like berberine reduce the affinity of destabilizing proteins (e.g., hnRNP D, KSRP) for the 3' UTR, thereby extending the transcript's half-life and increasing protein translation (1.3.1, 1.3.2). Other approaches include mRNA replacement therapy, which delivers exogenous functional LDLR mRNA via lipid nanoparticles or exosomes to restore receptor expression in deficient patients (1.1.1, 1.1.2), and the use of antisense oligonucleotides to inhibit microRNAs (such as miR-33) that naturally promote LDLR mRNA degradation (1.2.1, 1.4.3).